ReviewFrontiers in immunology2026
The GPR183-oxysterol axis in cancer: immune trafficking, spatial organization, and therapeutic potential.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
G protein-coupled receptor 183 (GPR183; also known as EBI2, Epstein-Barr virus-induced G-protein-coupled receptor 2) has emerged as a central regulator linking 7α,25-dihydroxycholesterol (7α,25-OHC) gradients to immune cell trafficking and tissue organization. In this review, we synthesize the structural, physiological, and oncogenic dimensions of the GPR183 axis. We first discuss the enzymatic biogenesis of its oxysterol ligand and the structural mechanisms underlying receptor activation. We then examine the context-dependent roles of GPR183 within the tumor microenvironment (TME), including receptor antagonism in hematological malignancies, modulation of immune organization in immunologically cold solid tumors. We further review the emerging relevance of spatial GPR183 profiling in relation to immune checkpoint blockade (ICB) responsiveness, as well as recent synthetic immunology strategies aimed at enhancing chimeric antigen receptor T (CAR-T) cell trafficking through oxysterol sensing. We identify and systematically analyze the central paradox of the GPR183 axis - namely, that identical 7α,25-OHC gradients can drive either anti-tumor tertiary lymphoid structure (TLS) formation or pro-tumor immunosuppressive myeloid cell recruitment - and discuss the potential determinants of this contextual polarity, including ligand concentration thresholds, spatial compartmentalization of oxysterol production, and receptor co-expression patterns. Collectively, current advances in the GPR183-oxysterol axis delineate new opportunities for metabolism-oriented immunotherapy and precision oncology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.